Influence Of Combined Cellular Immunotherapy And Chemotherapy On Clinical Outcome In Patients With Gastric Carcinoma.

Jiuwei Cui,Ling yu Li,Chang Wang,Hao fan Jin,Cheng Yao,Yi zhuo Wang,Dan Li,Hui min Tian,Chao Niu,Guan jun Wang,Wei Han,Jian ting Xu,Jing tao Chen,Wei Li
DOI: https://doi.org/10.1200/jco.2015.33.15_suppl.e15106
IF: 45.3
2015-01-01
Journal of Clinical Oncology
Abstract:e15106 Background: Despite the availability of multiple treatment strategies, patients with gastric carcinoma (GC) have a dismal prognosis. Cellular immunotherapy (CIT) with multiple autologous non-MHC restricted immunocytes, such as natural killer cells, AAT cells, and cytokine-induced killer cells, has synergistic antitumor effects with chemotherapy and can also reduce the possibility of immune escape. The aim of this study was to evaluate the efficacy and safety of CIT combined with chemotherapy in patients with GC. Methods: Patients were treated with the combination therapy (chemo/CIT group) or chemotherapy alone (control group). Progression-free survival (PFS), overall survival (OS), quality of life (QOL), and adverse events were investigated. Results: 83 eligible GC patients were enrolled, and only 58 patients with complete clinical data were analyzed, 30 in the chemo/CIT group and 28 in the control group. The median PFS of the chemo/CIT group was significantly longer compared with the control group...
What problem does this paper attempt to address?